These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 18845199)

  • 1. Analysis of adverse events of potential autoimmune aetiology in a large integrated safety database of AS04 adjuvanted vaccines.
    Verstraeten T; Descamps D; David MP; Zahaf T; Hardt K; Izurieta P; Dubin G; Breuer T
    Vaccine; 2008 Dec; 26(51):6630-8. PubMed ID: 18845199
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rebuttal Letter to the Letter to the Editor to "Analysis of adverse events of potential autoimmune aetiology in a large integrated safety database of AS04 adjuvanted vaccines" by T. Verstraeten et al.
    Verstraeten T
    Vaccine; 2009 Apr; 27(19):2530. PubMed ID: 19428857
    [No Abstract]   [Full Text] [Related]  

  • 3. The safety evaluation of adjuvants during vaccine development: the AS04 experience.
    Garçon N; Segal L; Tavares F; Van Mechelen M
    Vaccine; 2011 Jun; 29(27):4453-9. PubMed ID: 21527299
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine: a randomized, controlled trial in adolescent girls.
    Medina DM; Valencia A; de Velasquez A; Huang LM; Prymula R; García-Sicilia J; Rombo L; David MP; Descamps D; Hardt K; Dubin G;
    J Adolesc Health; 2010 May; 46(5):414-21. PubMed ID: 20413076
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term persistence of anti-HPV-16 and -18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine: modeling of sustained antibody responses.
    David MP; Van Herck K; Hardt K; Tibaldi F; Dubin G; Descamps D; Van Damme P
    Gynecol Oncol; 2009 Dec; 115(3 Suppl):S1-6. PubMed ID: 19217149
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity and safety of an experimental adjuvanted hepatitis B candidate vaccine in liver transplant patients.
    Nevens F; Zuckerman JN; Burroughs AK; Jung MC; Bayas JM; Kallinowski B; Rivas EF; Duvoux C; Neuhaus P; Saliba F; Buti M; Zarski JP; Pons F; Vanlemmens C; Hamtiaux V; Stoffel M
    Liver Transpl; 2006 Oct; 12(10):1489-95. PubMed ID: 16964595
    [TBL] [Abstract][Full Text] [Related]  

  • 7. AS04-adjuvanted human papillomavirus-16/18 vaccination: recent advances in cervical cancer prevention.
    Schwarz TF
    Expert Rev Vaccines; 2008 Dec; 7(10):1465-73. PubMed ID: 19053203
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in 10- to 14-year-old girls: open 6-year follow-up of an initial observer-blinded, randomized trial.
    Schwarz TF; Huang LM; Lin TY; Wittermann C; Panzer F; Valencia A; Suryakiran PV; Lin L; Descamps D
    Pediatr Infect Dis J; 2014 Dec; 33(12):1255-61. PubMed ID: 24978856
    [TBL] [Abstract][Full Text] [Related]  

  • 9. AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity.
    Didierlaurent AM; Morel S; Lockman L; Giannini SL; Bisteau M; Carlsen H; Kielland A; Vosters O; Vanderheyde N; Schiavetti F; Larocque D; Van Mechelen M; Garçon N
    J Immunol; 2009 Nov; 183(10):6186-97. PubMed ID: 19864596
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Meta-analysis of pregnancy outcomes in pooled randomized trials on a prophylactic adjuvanted glycoprotein D subunit herpes simplex virus vaccine.
    Tavares F; Cheuvart B; Heineman T; Arellano F; Dubin G
    Vaccine; 2013 Mar; 31(13):1759-64. PubMed ID: 23313657
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and immunogenicity profile of an experimental hepatitis B vaccine adjuvanted with AS04.
    Boland G; Beran J; Lievens M; Sasadeusz J; Dentico P; Nothdurft H; Zuckerman JN; Genton B; Steffen R; Loutan L; Van Hattum J; Stoffel M
    Vaccine; 2004 Dec; 23(3):316-20. PubMed ID: 15530674
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MF59-adjuvanted versus non-adjuvanted influenza vaccines: integrated analysis from a large safety database.
    Pellegrini M; Nicolay U; Lindert K; Groth N; Della Cioppa G
    Vaccine; 2009 Nov; 27(49):6959-65. PubMed ID: 19751689
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent clinical experience with vaccines using MPL- and QS-21-containing adjuvant systems.
    Garçon N; Van Mechelen M
    Expert Rev Vaccines; 2011 Apr; 10(4):471-86. PubMed ID: 21506645
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in adolescents aged 12-15 years: Interim analysis of a large community-randomized controlled trial.
    Lehtinen M; Eriksson T; Apter D; Hokkanen M; Natunen K; Paavonen J; Pukkala E; Angelo MG; Zima J; David MP; Datta S; Bi D; Struyf F; Dubin G
    Hum Vaccin Immunother; 2016 Dec; 12(12):3177-3185. PubMed ID: 27841725
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety of the AS04-adjuvanted human papillomavirus (HPV)-16/18 vaccine in adolescents aged 12-15 years: end-of-study results from a community-randomized study up to 6.5 years.
    Bi D; Apter D; Eriksson T; Hokkanen M; Zima J; Damaso S; Soila M; Dubin G; Lehtinen M; Struyf F
    Hum Vaccin Immunother; 2020 Jun; 16(6):1392-1403. PubMed ID: 31829767
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical development of AS04.
    Garçon N
    Methods Mol Biol; 2010; 626():15-27. PubMed ID: 20099118
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant Hepatitis B Vaccine Adjuvanted With AS04 in Dialysis Patients: A Prospective Cohort Study.
    Fabrizi F; Tarantino A; Castelnovo C; Martin P; Messa P
    Kidney Blood Press Res; 2015; 40(6):584-92. PubMed ID: 26566033
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Response to "Analysis of adverse events of potential autoimmune aetiology in a large integrated safety database of AS04 adjuvanted vaccines" by Verstraeten et al.
    Hildesheim A; Schiffman M; Solomon D; Wacholder S; Rodriguez AC; Herrero R
    Vaccine; 2009 Apr; 27(19):2529. PubMed ID: 19186195
    [No Abstract]   [Full Text] [Related]  

  • 19. Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted vaccine administered according to an alternative dosing schedule compared with the standard dosing schedule in healthy women aged 15 to 25 years: results from a randomized study.
    Esposito S; Birlutiu V; Jarcuska P; Perino A; Man SC; Vladareanu R; Meric D; Dobbelaere K; Thomas F; Descamps D
    Pediatr Infect Dis J; 2011 Mar; 30(3):e49-55. PubMed ID: 21273939
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Autoimmune disorders after immunisation with Influenza A/H1N1 vaccines with and without adjuvant: EudraVigilance data and literature review.
    Isai A; Durand J; Le Meur S; Hidalgo-Simon A; Kurz X
    Vaccine; 2012 Nov; 30(49):7123-9. PubMed ID: 23022149
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.